TICKERNERD
Menu
XERSXERSHealthcare · Drug Manufacturers - Specialty & Generic

XERS Stock Forecast: Xeris Biopharma Holdings, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.46
−2.74% on the day

The 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. hold a median 12-month price target of $12 — +60.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
81 / 100
Median analyst target
$12
Analysts covering
7
Revenue$92.1M+28.7% y/y
Operating income$5.2M
Net income−$31.1M
Free cash flow$8.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.2%
1M
−11.1%
YTD
−5.0%
1Y
−2.9%
From 52W high
−24.6%
From 52W low
+41.0%
$5.29
$9.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XERS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xeris Biopharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Value
98
Accruals
82
Growth
80
Volatility
72
Momentum
66
Size
41
Revisions
39
Issuance
15

Quality (98): The business earns solid, repeatable profits on what it owns.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XERS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XERS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26XERSHigh $18Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $8Median $12High $18

The green dot is the last close — the median target sits +60.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026Leerink PartnersMaintainsOutperform$12 → $16
20 Aug 2026BarclaysMaintainsOverweight$9.00 → $12
2 Mar 2026HC Wainwright & Co.ReiteratesBuy$10
2 Mar 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
9 Dec 2025BarclaysInitiatesOverweight—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
7 Nov 2025OppenheimerMaintainsOutperform—
7 Nov 2025Piper SandlerMaintainsNeutral—
29 Oct 2025OppenheimerMaintainsOutperform—
17 Sept 2025HC Wainwright & Co.MaintainsBuy—
19 Aug 2025Leerink PartnersMaintainsOutperform—
12 Aug 2025HC Wainwright & Co.AssumesBuy$10
8 Aug 2025Craig-HallumMaintainsBuy—
8 Aug 2025OppenheimerMaintainsOutperform—
5 June 2025Leerink PartnersMaintainsOutperform—
9 May 2025OppenheimerMaintainsOutperform—
7 Mar 2025Craig-HallumMaintainsBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025Leerink PartnersMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XERS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XERS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Xeris Biopharma Holdings, Inc. returned −2.9% against +17.5% for the S&P 500, dividends included.

XERS vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Oct 25Jan 26Apr 26Jul 26XERSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XERS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−102.3%
Analysts raising
0
Analysts cutting
3
Fundamentals

Xeris Biopharma Holdings, Inc. (XERS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
117.6×

Cheaper than 6% of US stocks

Price / sales
4.0×

Cheaper than 30% of US stocks

Price / book
−132.3×

Cheaper than 99% of US stocks

EV / EBITDA
31.3×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
28.7%

Higher than 77% of US stocks

Earnings growth (YoY)
28.7%

Higher than 65% of US stocks

Gross margin
86.4%

Higher than 95% of US stocks

Operating margin
5.6%

Higher than 56% of US stocks

Net margin
−5.1%

Higher than 24% of US stocks

Returns & dividend
Return on equity
4.0%

Higher than 52% of US stocks

Return on assets
6.1%

Higher than 82% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xeris Biopharma Holdings, Inc. (XERS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xeris Biopharma Holdings, Inc. has a market value of $1.4B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $335.4M. The latest quarter grew 28.7% year on year.

  • Net income over the same four quarters: −$17.2M, a −5.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.11.

  • Free cash flow in the twelve months to 30 June 2026: $55.7M, after $938K of capital spending.

  • Xeris Biopharma Holdings, Inc. spent $19.2M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 173.6M.

  • Trailing P/E: 117.6×; forward P/E: 19.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Xeris Biopharma Holdings, Inc. employs 435 people — $771K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

XERS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
XERSXeris Biopharma Holdings, Inc.$1.4B
81
HROWHarrow, Inc.$1.3B
47
PAHCPhibro Animal Health Corp.$1.4B
93
ANIPANI Pharmaceuticals, Inc.$1.6B
92
ETONEton Pharmaceuticals, Inc.$1.6B
99
AMPHAmphastar Pharmaceuticals, Inc.$1.0B
85
PCRXPacira Biosciences, Inc.$1.0B
99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xeris Biopharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XERS news & analysis

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

Seeking Alpha · 9 Sept 2026neutral

Xeris Biopharma Holdings discussed its XP-8121 program overview, Phase 3 study details, and commercial strategy in a transcript, as reported by Seeking Alpha. The item outlines company commentary on the program's development and market plans.

Why it matters — XERS watchers would care because the discussion provides insight into the company's progress and plans for its advanced XP-8121 pipeline candidate.

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Business Wire · 9 Sept 2026positive

Xeris Biopharma announced it will host an XP-8121 Program Overview webinar detailing its clinical development strategy, including the Cornerstone Phase 3 registrational study design, and the commercial opportunity for XP-8121, its investigational once-weekly subcutaneous levothyroxine for hypothyroidism.

Why it matters — The webinar provides XERS watchers with details on the development program and commercial prospects for its lead investigational once-weekly levothyroxine candidate.

Xeris Announces Details for XP-8121 Program Overview Webinar

Business Wire · 26 Aug 2026neutral

Xeris Biopharma announced details for a Program Overview webinar for XP-8121, its Phase 3-ready, once-weekly subcutaneous levothyroxine injection being developed to treat hypothyroidism. The webinar is scheduled for Wednesday, September.

Why it matters — The webinar provides an opportunity for investors to learn more about the company's late-stage hypothyroidism candidate, XP-8121, which is central to its pipeline.

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Seeking Alpha · 20 Aug 2026positive

Xeris Biopharma reported record 2024 revenues of $203M, up 24%, with growth across all three commercial products, and issued 2025 revenue guidance of $255M–$275M implying about 30% growth. The article also highlights XP-8121, a once-weekly injectable levothyroxine targeting a $1B+ U.S. market, pending Phase 3 trial initiation.

Why it matters — A XERS watcher would care because record revenue growth, raised guidance, and the potential blockbuster XP-8121 pipeline candidate point to the company's commercial progress and future growth prospects.

Xeris Biopharma Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Xeris Biopharma reported second-quarter total revenue of $92.1 million, up 29% year over year, with net product revenue rising 34% to $91 million. The company also raised the low end of its full-year 2026 revenue outlook to a range of $385 million to $390 million.

Why it matters — The strong quarterly revenue growth and upward revision to the full-year guidance signal improving commercial performance for Xeris watchers.

FAQ

Frequently asked questions about XERS stock

What is the XERS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XERS stock a buy right now?

Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xeris Biopharma Holdings, Inc. 81 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XERS?

As at 12 Sept 2026, Xeris Biopharma Holdings, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will XERS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +60.9% from the last close, and Ticker Nerd's factor model ranks Xeris Biopharma Holdings, Inc. 81 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XERS stock forecast for 2030?

No analyst covering Xeris Biopharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XERS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.

How has XERS stock performed over the past year?

Xeris Biopharma Holdings, Inc. returned -2.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xeris Biopharma Holdings, Inc. do?

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases.

What is the latest news on XERS?

The most recent item we track (Seeking Alpha, 9 Sept 2026): "Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript". Xeris Biopharma Holdings discussed its XP-8121 program overview, Phase 3 study details, and commercial strategy in a transcript, as reported by Seeking Alpha. The item outlines company commentary on the program's development and market plans.

Company

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases. Xeris Biopharma Holdings, Inc. markets Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, a treatment for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also works with proprietary formulation technologies designed to support liquid-stable, ready-to-use injectable medicines and reduce preparation steps for patients and caregivers. Its business is centered on specialty pharmaceuticals that address complex, often long-term conditions in endocrinology, neurology, and related areas, with a focus on patient-friendly delivery formats and commercial therapies already in market.

CEO Mr. John P. Shannon · 435 employees · United States · https://www.xerispharma.com